Annual Drug Patent Expirations for DAPTOMYCIN
Daptomycin is a drug marketed by Accord Hlthcare, Aspiro, Be Pharms, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hainan Poly Pharm, Hangzhou Zhongmei, Hengrui Pharma, Hisun Pharm Hangzhou, Hospira, Meitheal, Mylan, Mylan Labs Ltd, Qilu Pharm Hainan, Sagent Pharms Inc, Teva Pharms Usa, Xellia Pharms Aps, and Baxter Hlthcare Corp and, and is included in twenty-eight NDAs. It is available from twenty-four suppliers. There are two patents protecting this drug.
This drug has twenty-three patent family members in nineteen countries.
The generic ingredient in DAPTOMYCIN is daptomycin. Twenty-four suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the daptomycin profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com